Impairment of T and B cell development by treatment with a type I interferon. - Wikidata - awgldk - TriplyDB

Impairment of T and B cell development by treatment with a type I interferon.

Impairment of T and B cell development by treatment with a type I interferon.

http://www.wikidata.org/entity/Q36381045

about

Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction The effects of TLR activation on T-cell development and differentiation Regulation of the type I IFN induction: a current view Altered thymic function during interferon therapy in HCV-infected patients Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo IFN-α is constitutively expressed in the human thymus, but not in peripheral lymphoid organs.Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells Interferons mediate terminal differentiation of human cortical thymic epithelial cells.Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.The interplay of dendritic cell subsets in systemic lupus erythematosus.IFN-α produced by human plasmacytoid dendritic cells enhances T cell-dependent naïve B cell differentiation Plasmacytoid dendritic cells and the control of herpesvirus infections.Immature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination.Major differences in the responses of primary human leukocyte subsets to IFN-beta.Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor.Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression.Stimulated plasmacytoid dendritic cells impair human T-cell development Chronic spinal cord injury impairs primary antibody responses but spares existing humoral immunity in mice Immunization and infection change the number of recombination activating gene (RAG)-expressing B cells in the periphery by altering immature lymphocyte production.Neonatally induced inactivation of the vascular cell adhesion molecule 1 gene impairs B cell localization and T cell-dependent humoral immune response Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice.Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects.PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis Type I interferons in viral control and immune regulation Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors.Toll-like receptor 9 and interferon-γ receptor signaling suppress the B-cell fate of uncommitted progenitors in mice Villous B cells of the small intestine are specialized for invariant NK T cell dependence Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice Resident enteric microbiota and CD8+ T cells shape the abundance of marginal zone B cells.Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus.A perspective on B-cell-targeting therapy for SLE.A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.Daxx enhances Fas-mediated apoptosis in a murine pro-B cell line, BAF3.T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.

P2860

Q24309134-89CF9E09-88A9-470E-B774-AA164E6996A8 Q27001581-FF0C2509-E109-49BA-BC90-BFCA834C9F0B Q28276339-B08C53AF-D262-4CD4-B223-6A6F1F2A61ED Q28730551-21863A37-E5CB-4851-AF54-22DAA43B4A09 Q33374623-74EA08A6-F8FB-4212-9B83-114E75F0051A Q33533290-FD739330-BEA1-48C2-8439-96306B23EFA9 Q34014536-B033370E-F602-474B-BA14-638B1D1EBC99 Q34048667-EDB0734E-0992-41F2-9328-EF84D667F0CB Q34055580-26B76E50-E43B-4CB9-96EF-854E44BA467D Q34341479-1C1D89A0-32DD-4CCA-A54C-BE7229D023F0 Q34608946-0FA71ED9-8637-417E-9F8F-D72534076CC5 Q34842390-DEC6219F-649D-4320-8E1E-8E970C9195D8 Q35001944-0D26BEBC-455E-4626-BAAE-2DDC4C0CD571 Q35259804-0B00FC79-417B-4887-B318-04EC04C5ED8A Q35627706-80FF17A6-873D-4055-A4DF-D28B93473B3C Q35630626-5A4D2766-9898-4459-9DF2-CE1774BE7A7E Q35634878-9F6C0B43-AE33-4BD0-BCD4-FD9599C4484F Q35675526-44D55ECD-45C7-402A-A66C-6A37220D1C15 Q35826825-35004D76-6C94-420D-A0AF-6798092AC44A Q35834713-3946C047-F262-47B6-850F-BA6E42BAC186 Q35848849-92F1820D-7887-445D-8861-C6B76AF97B29 Q35981021-81323BF9-E91F-45F1-9D1F-79025DC91AEE Q36368599-95D4BB4C-E39A-49E5-B73E-AA866F4E1C9F Q36369285-4AA2AFA0-7FAA-47A9-9C57-0018B84778D5 Q36370602-62C8D469-A166-4830-9D4A-71B8D0474A30 Q36401305-FC9430B4-EE32-4F21-8B30-13C2491D56A5 Q36403595-1B1175EE-33EF-4B01-B70E-E067690E3859 Q36767643-1069268D-3F2D-4D1C-9959-A7BA4478E427 Q36990642-09D8E429-1068-4D03-9F4F-9327D01CA215 Q37019912-E9649B61-9566-4520-A257-666F35A0BB1F Q37196466-CF100AA1-C3AB-42DD-A779-17E26A63C82E Q37234883-9A114ACE-B027-475C-8992-18A663C4EA1B Q37325186-59FF0885-FDBC-4A92-8879-BE8A618048FC Q37535318-1BAA2BC2-4241-4825-893B-E8066BBA593D Q37577571-F8B2E6FD-BC98-4C8E-AD19-5F8F5B31F847 Q38537618-D764A443-9466-415B-BA19-1D89F1A2E049 Q39589343-3FC5A9D3-3717-42B9-A143-28CFC3719525 Q40656671-3D1143F9-B087-4598-A729-7D84E0649998 Q41049230-D166BD1F-9EA9-4715-A066-A68DEBBDB568 Q41952863-D1495C32-51A6-4895-BB33-245E99C65448

P2860

Impairment of T and B cell development by treatment with a type I interferon.

http://www.wikidata.org/entity/Q36381045

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Impairment of T and B cell development by treatment with a type I interferon.

@ast

Impairment of T and B cell development by treatment with a type I interferon.

@en

type

label

Impairment of T and B cell development by treatment with a type I interferon.

@ast

Impairment of T and B cell development by treatment with a type I interferon.

@en

prefLabel

Impairment of T and B cell development by treatment with a type I interferon.

@ast

Impairment of T and B cell development by treatment with a type I interferon.

@en

P1433

Q36381045-351DA51E-350E-47DF-87E6-0F813101D42B

P1476

Q36381045-6E2DE395-432C-48E1-9133-46976C8300DC

P2093

Q36381045-7F686EFD-07C6-4992-970B-683B75A1B608

Q36381045-CEC1CC84-0146-4AD9-A179-710E68F2E0CF

Q36381045-F73B4E22-5281-47C0-89F3-9A2CF50D4F4B

P2860

Q36381045-08855D3C-B812-43A3-8FD2-0640F1F95E9D

Q36381045-12278D31-CA20-4CDD-890A-A24FF60D5447

Q36381045-1652261A-00A6-44AE-B819-C34E872311C4

Q36381045-16677107-FC74-4434-A9B9-612ECEE739B7

Q36381045-1B46399C-D57E-415D-9F9F-EAD8C7A8EF98

Q36381045-1B6E2C37-CC5E-40CF-BD22-F160C7466EA7

Q36381045-235E20E2-B42F-4230-97C9-BC6CCCAAEA9B

Q36381045-2395C0F8-F5FB-4AF4-B119-A5E8DE1B7957

Q36381045-263E590F-EDFB-49E4-86A7-FEC3391B3B9F

Q36381045-26ECF267-B438-40FA-B7ED-F4CEA3FF2501

P304

Q36381045-B1005334-843E-4C58-9AEF-C7FEFC598C26

P31

Q36381045-7CCE2F2E-05FE-42C9-B0CA-76B6AC3C1F84

P356

Q36381045-1B75C58F-92EE-4CCC-83EC-139D0868B1F3

P407

Q36381045-D276CF3C-21D8-493C-9086-ACE67A24449D

P433

Q36381045-9A6FF7D6-B7CF-4691-88C4-4F980BDFEF51

P478

Q36381045-75AB4644-5CAC-4909-891D-ABEEF452F0EE

P577

Q36381045-F2CE1F88-D6AC-4D2D-9403-26FA3F52BA0B

P5875

Q36381045-ACDDF204-55E5-4F4A-B98A-6AB3EA904850

P698

Q36381045-F2486AB4-A7A7-4F72-B58F-28EA3A6F2504

P932

Q36381045-9B30AD0C-0A74-4E7B-8935-4325459763AE

P356

P1433

Journal of Experimental Medicine

P1476

Impairment of T and B cell development by treatment with a type I interferon.

@en

P2093

C Dong

http://www.w3.org/2001/XMLSchema#string

M D Cooper

http://www.w3.org/2001/XMLSchema#string

Q Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Functional role of type I and type II interferons in antiviral defense

Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture

Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes

Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells

Stimulation of B-cell progenitors by cloned murine interleukin-7

Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements

Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice

Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice

Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes

Somatic generation of antibody diversity

P304

79-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.187.1.79

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

1998-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13811473

http://www.w3.org/2001/XMLSchema#string

P698

9419213

http://www.w3.org/2001/XMLSchema#string

P932

2199191

http://www.w3.org/2001/XMLSchema#string